Clinical trials

Innovative Community Oncology Practices Selects Deep Lens’ VIPER™ as Preferred Clinical Trial Matching Solution for Network

Retrieved on: 
Friday, July 30, 2021
Other Health, Other Science, Pharmaceutical, Other Technology, Research, Oncology, Software, Medical devices, Hospitals, Data management, Science, Technology, Practice Management, Clinical trials, Managed care, General Health, Biotechnology, Health, Oncology, Innovative Community Oncology Practices, Deep Lens, INNOVATIVE COMMUNITY ONCOLOGY PRACTICES, DEEP LENS

Deep Lens and the Innovative Community Oncology Practices ( ICOP ) today announced a strategic partnership that will position Deep Lens VIPER as the preferred clinical trial program management technology solution for the 13-practice, U.S.-based network.

Key Points: 
  • Deep Lens and the Innovative Community Oncology Practices ( ICOP ) today announced a strategic partnership that will position Deep Lens VIPER as the preferred clinical trial program management technology solution for the 13-practice, U.S.-based network.
  • VIPER is an artificial intelligence-based solution that matches eligible patients to clinical trials right at the time of diagnosis.
  • Through this agreement, VIPER and other Deep Lens services will become available to all ICOP practices.
  • Innovative Community Oncology Practices (ICOP) is a conglomerate of 13 oncology practices nationwide designed to increase the scope of services and activities in the community oncology setting.

BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Retrieved on: 
Friday, July 30, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Orphan drugs, Health sciences, Breakthrough therapy, Health care, Antineoplastic drugs, Health, Benzamides, Sulfonamides, Venetoclax, SEQUOIA, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, BRUKINSA, BeiGene, SEQUOIA, CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA, BRUKINSA, BEIGENE

Long-term results from BGB-3111-205 with a median follow-up time of 34 months were reported at the EHA2021 Congress in June 2021.

Key Points: 
  • Long-term results from BGB-3111-205 with a median follow-up time of 34 months were reported at the EHA2021 Congress in June 2021.
  • SEQUOIA is a randomized, multicenter, global Phase 3 trial (NCT03336333) designed to evaluate the efficacy and safety of BRUKINSA compared to B+R in patients with TN CLL or SLL.
  • Patients with del(17p) were not randomized to B+R, as they experience poor clinical outcomes and poor response to chemoimmunotherapy.
  • This cohort of patients with del(17p) achieved significant efficacy with an 18-month PFS of 90.6%, as assessed by investigator.

GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps

Retrieved on: 
Thursday, July 29, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Branches of biology, Otorhinolaryngology, Organ systems, Nose, Olfactory system, Sensory organs, Nasal polyp, Respiratory system, Nasal cavity, Polyp, Rhinorrhea, Sinus, chronic rhinosinusitis with nasal polyps (CRSwNP), mepolizumab, GSK, CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP), MEPOLIZUMAB, GSK

It is often characterised by raised eosinophil levels, in which soft tissue growth, known as nasal polyps, develop in the sinuses and nasal cavity.

Key Points: 
  • It is often characterised by raised eosinophil levels, in which soft tissue growth, known as nasal polyps, develop in the sinuses and nasal cavity.
  • CRSwNP can cause chronic symptoms such as nasal obstruction, loss of smell, facial pressure and nasal discharge.
  • GSK is committed to exploring the role of IL-5 inhibition in eosinophil-driven diseases to help address unmet needs of patients.
  • Mepolizumab achieved significant improvement in reducing the size of nasal polyps and nasal obstruction.

Usona Institute Campus Information Briefing & Groundbreaking

Retrieved on: 
Thursday, July 29, 2021
Alternative medicine, Mental health, Health, Clinical trials, Research, Science, Pharmaceutical, Food and Drug Administration, United States Public Health Service

Click here for map and please follow the directional signs to the site location.

Key Points: 
  • Click here for map and please follow the directional signs to the site location.
  • The site is unpaved so please dress comfortably with appropriate shoes for uneven ground.
  • Usona Institute works across the spectrum from drug discovery and clinical research to FDA approval and delivery of care.
  • Usona Institute is a non-profit medical research organization created to serve the public good with an open science model of operation.

Seagen Reports Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, July 29, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical trials, SeaGen

Cost of Sales: Cost of sales for the second quarter and year-to-date in 2021 were $78.1 million and $142.2 million, respectively, compared to $48.2 million and $77.7 million for the same periods in 2020.

Key Points: 
  • Cost of Sales: Cost of sales for the second quarter and year-to-date in 2021 were $78.1 million and $142.2 million, respectively, compared to $48.2 million and $77.7 million for the same periods in 2020.
  • Net Loss: Net loss for the second quarter of 2021 was $84.6 million, or $0.47 per diluted share, compared to net loss of $21.2 million, or $0.12 per diluted share, for the second quarter of 2020.
  • Seagen anticipates 2021 revenues, operating expenses and other costs to be in the ranges shown in the table below, unchanged from the Company's previous financial guidance provided on February 11, 2021.
  • Seagen management will host a conference call and webcast with supporting slides to discuss its second quarter 2021 and year-to-date financial results and provide an update on business activities.

Better Therapeutics and Colorado Prevention Center Clinical Research Launch Real-World Evidence Study of Prescription Digital Therapeutic for Type 2 Diabetes

Retrieved on: 
Thursday, July 29, 2021
Software, Pharmaceutical, Health, Diabetes, Data management, Technology, Clinical trials, Mobile, Wireless, Behavior modification, Digital therapeutics, Colorado Prevention Center (CPC) Clinical Research, Better Therapeutics, Mountain Crest Acquisition Corp. II, COLORADO PREVENTION CENTER (CPC) CLINICAL RESEARCH, BETTER THERAPEUTICS, MOUNTAIN CREST ACQUISITION CORP. II

BT-001 is an investigational, prescription digital therapeutic that delivers a novel form of cognitive behavioral therapy to patients with uncontrolled type 2 diabetes.

Key Points: 
  • BT-001 is an investigational, prescription digital therapeutic that delivers a novel form of cognitive behavioral therapy to patients with uncontrolled type 2 diabetes.
  • The open-label, randomized, controlled study will evaluate approximately 500 patients with type 2 diabetes in the University of Colorado (UC) Health System using BT-001.
  • At Better Therapeutics, we believe the system of care desperately needs therapeutics that address the root causes of disease, said Mark Berman, MD, Chief Medical Officer of Better Therapeutics.
  • BT-001 is Better Therapeutics lead product candidate among their pipeline of FDA-regulated, prescription digital therapeutics designed to treat the underlying cause of a range of cardiometabolic conditions.

Immuno-oncology Clinical Trials Market Research Report 2021: Analysis by Phase (Phase I, Phase II, Phase III, Phase IV), Design (Interventional Trials, Observational Trials), & Indication - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Pharmaceutical, Health, Oncology, Clinical trials, Health sciences, Health, Clinical research, Clinical trial, Design of experiments, Drug discovery, Pharmaceutical industry

The "Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Design (Interventional Trials, Observational Trials), by Indication, by Region and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Design (Interventional Trials, Observational Trials), by Indication, by Region and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global immuno-oncology clinical trials market size is expected to reach USD 15.1 billion by 2028.
  • The rapidly growing field of Immuno-oncology has emerged as a novel therapeutic area within the oncology ecosystem, transforming the treatment of cancer.
  • At the end of 2019, over 40.0% of current immuno-oncology clinical experiments involved at least one location in the region
    Chapter 3 Immuno-oncology clinical trials Market: Variables, Trends, & Scope
    Chapter 4 Immuno-oncology Clinical Trials Market: Phase Segment Analysis
    4.1 Immuno-oncology Clinical Trials Market: Phase Market Share Analysis, 2020 & 2028

Global Fatigue Clinical Trials Review, H2 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Health, Clinical trials, Health sciences, Health, Pharmaceutical industry, Clinical research, Medical research, Clinical trials, Drug discovery, Food and Drug Administration, Clinical trials in India

The "Fatigue - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fatigue - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Fatigue - Global Clinical Trials Review, H2, 2021" provides an overview of the Fatigue Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Fatigue.
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Clinical Trials by G7 Countries: Proportion of Fatigue to Central Nervous System Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Fatigue to Central Nervous System Clinical Trials